IVI epoprostenol as salvage therapy in pulmonary arterial hypertension: An Australian perspective

Matthew R Salamonsen, Dominic Keating, Helen Whitford, Michael Bailey, T Miller, C Manterfield, Trevor John Williams

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


IVI epoprostenol is the only therapy for pulmonary arterial hypertension (PAH) with a randomized controlled trial demonstrating improved survival, when used as first-line monotherapy. In Australia it is used as salvage therapy for those failing treatment with other targeted therapies or presenting in World Health Organization functional class (FC) IV.
Original languageEnglish
Pages (from-to)245 - 251
Number of pages7
JournalInternal Medicine Journal
Issue number3
Publication statusPublished - 2011

Cite this